NEW YORK (GenomeWeb News) – Toronto-based Spectral Diagnostics said today it will provide Bio-Rad Pasteur with single chain Troponin I reagents under a license and supply agreement.
Spectral CEO Paul Walker said the “consistent revenue stream” from the agreement will generate capital the company needs to commercialize its FDA-approved endotoxemia assay, which also tests for the subsequent risk of sepsis.
Financial terms of the agreement were not released.